Login / Signup

Inhaled molgramostim therapy for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP): a plain language summary of the IMPALA trial.

Bruce C Trapnell
Published in: Hospital practice (1995) (2024)
Keyphrases
  • pulmonary hypertension
  • multiple sclerosis
  • clinical trial
  • autism spectrum disorder
  • study protocol
  • cystic fibrosis
  • phase iii
  • randomized controlled trial
  • open label